Assessment of GARP Expression in Acute and Chronic Coronary Syndrome (GARP-CS)

February 12, 2026 updated by: Université Catholique de Louvain

Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

600

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
      • Brussels, Belgium, 1200
        • Cliniques Universitaires Saint-luc
        • Contact:
        • Principal Investigator:
          • Christophe Beauloye, Medical Degree
        • Sub-Investigator:
          • Louis Charki, Medical Degree
        • Sub-Investigator:
          • Shakeel Kautbally, Medical Degree

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Older than 18 years
  • Able to give informed consent
  • Undergoing coronary angiography.

Exclusion Criteria:

  • Patients younger than 18 years
  • Unable to give consent
  • Pregnancy
  • Dialysis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acute coronary syndrome
This arm includes patients undergoing coronary angiography with a final diagnostic of acute coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.
Biological: Arterial blood sample
An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.
Experimental: Chronic coronary syndrome
This arm includes patients undergoing coronary angiography with a final diagnostic of chronic coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.
Biological: Arterial blood sample
An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.
Experimental: Control
This arm includes patients undergoing coronary angiography with a final diagnostic of non significant coronary disease. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination.
Biological: Arterial blood sample
An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet GARP expression
Time Frame: Throughout the entire study, approximately during 2 years
The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.
Throughout the entire study, approximately during 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inflammatory profile
Time Frame: Throughout the entire study, approximately during 2 years
The inflammatory cytokines (IL-1, IL-6, TNF,...) profile will be determined by multiplex and compared between arms.
Throughout the entire study, approximately during 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université Catholique de Louvain

Collaborators

Fonds National de la Recherche Scientifique

Investigators

  • Principal Investigator: Christophe Beauloye, Medical Degree, Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Study Registration Dates

First Submitted

January 26, 2026

First Submitted That Met QC Criteria

January 26, 2026

First Posted (Actual)

February 3, 2026

Study Record Updates

Last Update Posted (Actual)

February 17, 2026

Last Update Submitted That Met QC Criteria

February 12, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GARP-CS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atheroma; Heart

Clinical Trials on Arterial blood sample

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe